After adjustment for various prognostic factors and treatments, a BRCA2 mutation was associated with a significantly worse prognosis than a sporadic breast cancer (HR = 1.61; 95% CI 1.11–2.35, p = 0.01). This evidence concerns the gene BRCA2 and breast carcinoma.